Comparative Pharmacology
Head-to-head clinical analysis: LEVAQUIN IN DEXTROSE 5 IN PLASTIC CONTAINER versus TROVAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEVAQUIN IN DEXTROSE 5 IN PLASTIC CONTAINER versus TROVAN.
LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER vs TROVAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Levofloxacin is a fluoroquinolone antibacterial that inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, thereby inhibiting DNA replication and transcription.
Trovan (trovafloxacin) is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, thereby blocking DNA replication and transcription.
750 mg intravenously every 24 hours for 5 days. Alternatively, 500 mg intravenously every 24 hours for 7-14 days depending on infection.
200 mg IV once daily for 7-14 days for community-acquired pneumonia; 200 mg orally once daily for 7-14 days for acute exacerbation of chronic bronchitis
None Documented
None Documented
Terminal elimination half-life is approximately 6-8 hours in patients with normal renal function (creatinine clearance >80 mL/min); prolonged in renal impairment (up to 30-50 hours in severe impairment).
Terminal elimination half-life is approximately 10-12 hours in patients with normal renal function, supporting twice-daily dosing.
Primarily renal excretion as unchanged drug (approximately 87% within 48 hours); less than 4% as metabolites; biliary/fecal excretion accounts for <5%.
Renal (approximately 60% unchanged) and fecal/biliary (approximately 35% as unchanged drug and metabolites).
Category C
Category C
Antibiotic (Fluoroquinolone)
Antibiotic (Fluoroquinolone)